News & Events

New plasma filtration system stops hemorrhage

Date 4/13/2021 12:00:00 AM 

NAZARETH, Israel, 13 April 2021 – Plas-Free, an NGT3 VC portfolio company, has successfully completed the open label phase of its recent clinical trial by enrolling 5 patients with upper gastrointestinal bleeding in Israel.

In parallel, the Company has recruited 5 additional patients in its multi-center (Italy and Czech Republic), double blind, randomized clinical study on upper gastrointestinal bleeding. It's planned that the Israeli sites will join the multi-center study following the approval of the safety of the open label phase by the Israeli Ministry of Health.  Click here to continue... 


Investors - Contact Us

Entrepreneurs - Contact Us